Showing 31 - 40 of 68,654
Recent political events have thrust the bulk negotiation of drug prices by Medicare and Medicaid back into the spotlight. Yet, even if politically feasible, there is no clear framework for negotiating prices of new drugs with uncertain target populations - for example, due to imprecise estimates...
Persistent link: https://www.econbiz.de/10011788784
I study the effect of reference pricing on competition by parallel imports, in particular the market share of parallel imports and the number of parallel traders. First, I analyze the effect of reference pricing on competition by parallel imports in a vertical differentiation model with a...
Persistent link: https://www.econbiz.de/10011949019
I evaluate how the probability of substitution of a prescribed drug in a pharmacy depends on the pharmacists' profits and patients' out of pocket costs. I use Finnish population-wide data covering all prescriptions of three popular antidepressants. I find that one euro increase in the total...
Persistent link: https://www.econbiz.de/10011954334
In many healthcare markets, physicians can influence the volume (volume response) and the composition of the services provided (substitution response). The goal and main contribution of this paper is to empirically assess the relative importance of these two behavioral channels. Our analysis is...
Persistent link: https://www.econbiz.de/10011384026
The German health care reform of 1997 provides a natural experiment for evaluating the price sensitivity of demand for physicians' services. As a part of the reform, co-payments for prescription drugs were increased step up to 200%. However, certain groups of people were exempted from the...
Persistent link: https://www.econbiz.de/10001806923
This study seeks to provide evidence for deciding whether or not a pharmaceutical innovation should be included in the benefit list of social health insurance. A discrete choice experiment (DCE) was conducted in Germany to measure preferences for modern insulin therapy. Of the 1,100 individuals...
Persistent link: https://www.econbiz.de/10003900791
-savings, and that patients' copayments decrease despite the extra surcharges under RP. -- pharmaceuticals ; regulation ; generic …
Persistent link: https://www.econbiz.de/10008749029
We study the Medicare Part D prescription drug insurance program as a bellwether for designs of private, non-mandatory health insurance markets that control adverse selection and assure adequate access and coverage. The focus of this paper is on the ability of consumers to evaluate and optimize...
Persistent link: https://www.econbiz.de/10009666978
Many countries with national health care providers and health insurances regulate the market for pharmaceuticals to … (no. of firms) suggests a significant but small negative correlation with prices. -- pharmaceuticals ; prices ; co …
Persistent link: https://www.econbiz.de/10009522774
In recent years, consumer choice has become an important element of public policy. One reason is that consumers differ in their tastes and needs, which they can express most easily through their own choices. Elements that strengthen consumer choice feature prominently in the design of public...
Persistent link: https://www.econbiz.de/10009656193